Z-Ile-Leu-aldehyde - 96%, high purity , CAS No.161710-10-7

Item Number

Z648092

Grouped product items
SKU	Size	Availability	Price
Z648092-1mg	1mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$200.90
Z648092-2mg	2mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$194.90
Z648092-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$420.90
Z648092-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$600.90

View related series

Basic Description

Specifications & Purity	96%
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Product Description	Z-Ile-Leu-aldehyde (Z-IL-CHO) is a potent and competitive peptide aldehyde inhibitor of γ-secretase and notch. In Vitro Z-Ile-Leu-aldehyde (ILCHO) significantly downregulates Th17-associated cytokine levels in murine Th17 in vitro polarization assays. Z-Ile-Leu-aldehyde (GSI XII) induces apoptosis of murine MOPC315.BM myeloma cells with high Notch activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRsup> Cell Line: CD4 + T cells from C57BL/6 mice. Concentration: 25 μM. Incubation Time: 24, 48, 72 hours. Result: DownregulateD RORt and IL-17 mRNA expression. Cell Viability Assaysup> Cell Line: MOPC315.BM cells. Concentration: 0, 12, 15 μM. Incubation Time: 24-48 h hours. Result: Reduced viability and induced apoptosis in MOPC315.BM cells In Vivo Z-Ile-Leu-aldehyde (GSI XII, 10 mg/kg, Intraperitoneally either for 14 days) controls myeloma bone disease mainly by targeting Notch in MM cells and possibly in osteoclasts in their microenvironment. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MOPC315.BM mouse model. Dosage: 10 mg/kg. Administration: Intraperitoneally either for 14 days. Result: Reduces myeloma-specific paraprotein levels in the MOPC315.BM model. Diminished osteolytic lesions in the MOPC315.BM mice. Form:Solid

Names and Identifiers

IUPAC Name	benzyl N-[(2S,3S)-3-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]carbamate
INCHI	InChI=1S/C20H30N2O4/c1-5-15(4)18(19(24)21-17(12-23)11-14(2)3)22-20(25)26-13-16-9-7-6-8-10-16/h6-10,12,14-15,17-18H,5,11,13H2,1-4H3,(H,21,24)(H,22,25)/t15-,17-,18-/m0/s1
InChi Key	WJQLUFQGNVGLKR-SZMVWBNQSA-N
Canonical SMILES	CCC(C)C(C(=O)NC(CC(C)C)C=O)NC(=O)OCC1=CC=CC=C1
Isomeric SMILES	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C=O)NC(=O)OCC1=CC=CC=C1
PubChem CID	44366908
MeSH Entry Terms	benzyloxycarbonyl-isoleucyl-leucinal;GSI-XII cpd;Z-IL-CHO;Z-Ile-Leu-CHO
Molecular Weight	362.46

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description